New antibody shot could shield against Tick-Borne brain virus
NCT ID NCT07377253
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a lab-made antibody called TBE025 in 18 healthy adults aged 18 to 55. The goal is to see if it is safe and how the body processes it when given through a vein. Participants receive one dose and are closely monitored for side effects. This research helps determine the right dose for future studies aiming to prevent tick-borne encephalitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Universitaire Hospitalier Vaudois (CHUV)
Lausanne, Canton of Vaud, 1011, Switzerland